RxDoctor Payments Data

William Schmitt, DO

Family Medicine · Independence, IANPI 1053792887

Payments from drug & device makers

$910in general payments, 2019–2025

Across 67 payments — averaging $13.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$161
  • AbbVie$156
  • AstraZeneca$146
  • Novo Nordisk$79
  • Boehringer Ingelheim$76
  • Pfizer$47
  • plus $245 from 11 others

What the payments were for

  • Food & beverage$910100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$910 in reported general payments places this provider in the 80th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$10,146
Medicare patients
55
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$92,625
OzempicSemaglutide76$77,436
EliquisApixaban134$62,390
XareltoRivaroxaban69$47,884
MounjaroTirzepatide17$23,074
EntrestoSacubitril/Valsartan44$22,579
Repatha SureclickEvolocumab38$20,895
NuedextaDextromethorphan Hbr/Quinidine13$12,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,504
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$9,720
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,339
TradjentaLinagliptin26$6,865
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$6,192
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$5,856
Spiriva RespimatTiotropium Bromide11$5,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$76$105,137153 claims
Novo NordiskOzempic$79$77,43676 claims
PfizerEliquis$47$62,390134 claims
Johnson & JohnsonXarelto$161$47,88469 claims
Lilly USA, LLCMounjaro, Insulin Lispro$28$24,11734 claims
NovartisEntresto$12$22,57944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Independence

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →